Phase II neoadjuvant trial of Albumin-Bound Paclitaxel, Trastuzumab and Pertuzumab followed by anthracycline based regimens in patients with operable Her2 positive breast cancer (OMC-BC05)

被引：0
|
作者：
Iwamoto, M. [1 ]
Matsutani, A. [1 ]
Ikari, A. [1 ]
Tominaga, T. [1 ]
Maezawa, S. [1 ]
Oku, H. [1 ]
Kimura, K. [1 ]
机构：
[1] Osaka Med Coll, Breast Surg, Osaka, Japan
来源：
BREAST | 2021年 / 56卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P086
引用
收藏
页码：S52 / S52
页数：1
相关论文
共 50 条
  • [31] Association between HER2 status and response to neoadjuvant anthracycline followed by paclitaxel plus carboplatin chemotherapy without trastuzumab in breast cancer
    Lu Yao
    Juan Zhang
    Yiqiang Liu
    Tao Ouyang
    Jinfeng Li
    Tianfeng Wang
    Zhaoqing Fan
    Tie Fan
    Benyao Lin
    Yuntao Xie
    Chinese Journal of Cancer Research, 2015, 27 (06) : 553 - 561
  • [32] The efficacy and safety of trastuzumab and albumin-bound paclitaxel with or without pyrotinib as neoadjuvant therapy for HER2-positive breast cancer: a prospective observational cohort study
    Wang, Yu
    Xu, Yanlong
    Liu, Xuefeng
    Li, Cong
    Wang, Jiapeng
    Zhang, Xinyue
    Shao, Bin
    Zhang, Jianguo
    GLAND SURGERY, 2024, 13 (05) : 654 - 662
  • [33] A Phase II Neoadjuvant Trial of Sequential Nanoparticle Albumin-Bound Paclitaxel Followed by 5-Fluorouracil/Epirubicin/Cyclophosphamide in Locally Advanced Breast Cancer
    Robidoux, Andre
    Buzdar, Aman U.
    Quinaux, Emmanuel
    Jacobs, Samuel
    Rastogi, Priya
    Fourchotte, Virginie
    Younan, Rami J.
    Pajon, Eduardo R.
    Shalaby, Ibrahim A.
    Desai, Ajit M.
    Fehrenbacher, Louis
    Geyer, Charles E., Jr.
    Mamounas, Eleftherios P.
    Wolmark, Norman
    CLINICAL BREAST CANCER, 2010, 10 (01) : 81 - 86
  • [34] Phase I/II study of neoadjuvant eribulin mesylate, carboplatin, and trastuzumab (ECH) for operable HER2 positive (HER2+) breast cancer.
    Schwartzberg, Lee Steven
    Tauer, Kurt W.
    Hermann, Robert C.
    Nikolinakos, Petros G.
    Houts, Arthur C.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [35] Phase I/II study of neoadjuvant carboplatin, eribulin mesylate, and trastuzumab (ECH) for operable HER2 positive (HER2+) breast cancer.
    Schwartzberg, Lee Steven
    Tauer, Kurt W.
    Hermann, Robert C.
    Nikolinakos, Petros G.
    Houts, Arthur C.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [36] A randomized, controlled phase II trial of neoadjuvant ado-trastuzumab emtansine, lapatinib, and nab-paclitaxel versus trastuzumab, pertuzumab, and paclitaxel in HER2-positive breast cancer (TEAL study)
    Patel, Tejal A.
    Ensor, Joe E.
    Creamer, Sarah L.
    Boone, Toniva
    Rodriguez, Angel A.
    Niravath, Poly A.
    Darcourt, Jorge G.
    Meisel, Jane L.
    Li, Xiaoxian
    Zhao, Jing
    Kuhn, John G.
    Rosato, Roberto R.
    Qian, Wei
    Belcheva, Anna
    Schwartz, Mary R.
    Kaklamani, Virginia G.
    Chang, Jenny C.
    BREAST CANCER RESEARCH, 2019, 21 (01)
  • [37] A randomized, controlled phase II trial of neoadjuvant ado-trastuzumab emtansine, lapatinib, and nab-paclitaxel versus trastuzumab, pertuzumab, and paclitaxel in HER2-positive breast cancer (TEAL study)
    Tejal A. Patel
    Joe E. Ensor
    Sarah L. Creamer
    Toniva Boone
    Angel A. Rodriguez
    Poly A. Niravath
    Jorge G. Darcourt
    Jane L. Meisel
    Xiaoxian Li
    Jing Zhao
    John G. Kuhn
    Roberto R. Rosato
    Wei Qian
    Anna Belcheva
    Mary R. Schwartz
    Virginia G. Kaklamani
    Jenny C. Chang
    Breast Cancer Research, 21
  • [38] Randomized Phase II Study of Primary Systemic Chemotherapy and Trastuzumab for Operable HER2 Positive Breast Cancer
    Nakamura, Seigo
    Ando, Masashi
    Masuda, Norikazu
    Aogi, Kenjiro
    Ino, Hiroyo
    Iwata, Hiroji
    Tokuda, Yutaka
    Yamamoto, Naohito
    Kasai, Hiroi
    Takeuchi, Masahiko
    Tsuda, Hitoshi
    Akiyama, Futoshi
    Kurosumi, Masafumi
    Fujiwara, Yasuhiro
    CLINICAL BREAST CANCER, 2012, 12 (01) : 49 - 56
  • [39] Nanoparticle albumin-bound paclitaxel-based neoadjuvant regimen: A promising treatment option for HER2-low-positive breast cancer
    Shi, Wenjie
    Wan, Xinyu
    Wang, Ye
    He, Jinzhi
    Huang, Xiaofeng
    Xu, Yinggang
    Zhang, Weiwei
    Chen, Rui
    Wang, Lexin
    Zheng, Ran
    Ma, Lingjun
    Li, Xuan
    Xu, Lu
    Zha, Xiaoming
    Wang, Jue
    NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE, 2023, 49
  • [40] Phase II prospective open label study of neoadjuvant pertuzumab, trastuzumab, and nab-paclitaxel in patients with HER-2 positive advanced breast cancer.
    Lavasani, Sayeh Moazami
    Yost, Susan Elaine
    Frankel, Paul Henry
    Ruel, Christopher
    Murga, Mireya
    Tang, Aileen
    Martinez, Norma
    Kruper, Laura
    Tumyan, Lusine
    Schmolze, Dan
    Menghi, Francesca
    Liu, Edison T.
    Yeon, Christina Haeyoung
    Yuan, Yuan
    Waisman, James Ross
    Somlo, George
    Mortimer, Joanne E.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
12345